Bart S. Hendriks - Concepedia

Author

Bart S. Hendriks

Merrimack Pharmaceuticals (United States)ORCID

Also Known As

B Hendriks, B. Hendriks, B.S. Hendriks, BART HENDRIKS, BS Hendriks, Bart Hendriks, Bart S Hendriks, Bart S. Hendriks, Gavin Macbeath, Hang, Ta-Chun

117

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Merrimack Pharmaceuticals (United States)Massachusetts Institute of Technology Dana-Farber Cancer Institute The Barbara Ann Karmanos Cancer Institute Pfizer (United States)

About

Bart S. Hendriks is an author at Merrimack Pharmaceuticals (United States) specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	16	1.1K
2	Engineering	4	4	160
3	Health Sciences	3	3	203
4	Natural Sciences	2	2	101
5	Allergy	1	1	140

Bart S. Hendriks

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer Helen Lee, Anthony F. Shields, Barry A. Siegel, Clinical Cancer Research	2017	359
Quantitative Analysis of HER2-mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis Bart S. Hendriks, Lee K. Opresko, H Wiley, Journal of Biological Chemistry	2003	180
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study Ramesh K. Ramanathan, Ronald L. Korn, Natarajan Raghunand, Clinical Cancer Research	2017	171
Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Bart S. Hendriks, Lee K. Opresko, H Wiley, PubMed Her2 Overexpression EffectsHuman GrowthImmunologyDermatologyTumor Biology	2003	140
Synergistic drug–cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity Benjamin D. Cosgrove, Bracken M. King, Maya A. Hasan, Toxicology and Applied Pharmacology InflammationHepatologyHepatocellular DeathMedicineLiver Physiology	2009	138
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer Christopher W. Espelin, Shannon C. Leonard, Elena Geretti, Cancer Research Breast OncologyCombined Mm-302/trastuzumab TherapyTumor BiologyHer2 ReceptorLiposomal-encapsulated Doxorubicin	2016	122
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study Pamela N. Münster, Ian E. Krop, Patricia LoRusso, British Journal of Cancer	2018	117
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours Mark R. Middleton, Emma Dean, T.R. Jeffry Evans, British Journal of Cancer	2021	114
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity Joseph G. Reynolds, Elena Geretti, Bart S. Hendriks, Toxicology and Applied Pharmacology Tumor BiologyOncologyAnti-tumorigenic EffectsMedicineTumor Targeting	2012	112
Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients Matthew Onsum, Elena Geretti, Violette Paragas, American Journal Of Pathology MedicinePathologyHer2-positive PatientsMolecular DiagnosticsSingle-cell Analysis	2013	105

Page 1